

EGFR and HER2 Activate Rigidity Sensing Only on Rigid Matrices

Mayur Saxena^{1,*}, Shuaimin Liu^{2,*}, Bo Yang³, Cynthia Hajal², Rishita Chandede³, Junqiang Hu²,
Haguy Wolfenson^{4,5,#}, James Hone^{2,#}, and Michael P. Sheetz^{3,4,#}

¹Department of Biomedical Engineering, Columbia University, New York, New York 10027, USA

²Department of Mechanical Engineering, Columbia University, New York, New York 10027, USA

³Mechanobiology Institute, National University of Singapore, Singapore 117411, Singapore

⁴Department of Biological Sciences, Columbia University, New York, New York 10027, USA

⁵Current address: Department of Genetics and Developmental Biology, The Ruth and Bruce Rappaport Faculty of Medicine, The Technion – Israel Institute of Technology, Haifa, Israel 31096

*These authors have made equal contributions

#Corresponding author

Supplementary Discussion

In this study, we show that EGFR and HER2 play a key role in rigidity sensing and directly affect CU formation. We find that during cell spreading, the formation of CUs is dramatically inhibited by blocking EGFR activity with the consequence that cell spread area is substantially decreased. The inhibition of SFK activity has a similar effect on CU activity and on spread area, which is consistent with earlier reports that Src kinase is responsible for non-ligand dependent activation of EGFR^{1,2}. Furthermore, SFK mediated tyrosine phosphorylation can also activate overexpressed HER2 to substitute for EGFR in this pathway and enable rigidity sensing by the cell.

There is an extensive literature on EGFR because it has a major role in many cancers and growth abnormalities³⁻⁵. Our findings indicate that the non-ligand dependent activation of EGFR affects CU activity which we previously showed was important for rigidity sensing^{6,7}. A simple hypothesis to explain the results is that EGFR is a critical part of a positive feedback system that is activated by rigid matrices. Since only a few studies of EGFR have been done on soft

32 surfaces⁸, the lack of EGFR involvement in cell function on soft surfaces has not been well
33 characterized. However, elements of the process can be understood.

34 Ligand-independent activation of EGFR is linked to Src activation of EGFR but only on rigid
35 surfaces⁹. Our studies are consistent with SFK activation of EGFR that is dependent upon
36 rigidity sensing and indicates that the recruitment of pEGFR to rigid adhesion sites depends upon
37 SFK. Not only do the antibodies to the Src phosphorylation site on EGFR localize better to the
38 adhesions than does the antibody to the autophosphorylation site, but also the inhibition of SFK
39 has the same effect on spreading and CU activity as does the inhibition of EGFR kinase.

40 Our findings also highlight the transient nature of the EGFR effects. It is known that addition of
41 EGF results in a transient (~1-3 minutes) activation of the EGFR that causes endocytosis and
42 transport to the nucleus¹⁰. This addition of EGF to spread cells causes a dramatic increase in CU
43 activity concomitant with the commonly observed rapid spreading. This effect of EGF is
44 dependent upon myosin contractility and substrate rigidity, implying that there may be a positive
45 feedback cycle for EGFR recruitment and activation of CU formation. The CUs are also dynamic
46 since the contraction-relaxation cycle lasts only a minute¹¹; and in stably spread cells, the level of
47 CU activity is both very low and intermittent. However, on stiff surfaces, the CU activity causes
48 the stabilization of adhesions and growth for many fibroblasts. If EGFR is an integral part of the
49 system that causes CU assembly at adhesion sites, then it could also only transiently interact with
50 the adhesions. Indeed, we find that the ratio of pEGFR to paxillin decreases upon adhesion
51 maturation.

52


53 **References**

54

- 55 1. Andreev, J. *et al.* Src and Pyk2 mediate G-protein-coupled receptor activation of epidermal
56 growth factor receptor (EGFR) but are not required for coupling to the mitogen-activated
57 protein (MAP) kinase signaling cascade. *J. Biol. Chem.* **276**, 20130–20135 (2001).

- 58 2. Moro, L. *et al.* Integrin-induced epidermal growth factor (EGF) receptor activation requires
59 c-Src and p130Cas and leads to phosphorylation of specific EGF receptor tyrosines. *J. Biol.*
60 *Chem.* **277**, 9405–9414 (2002).
- 61 3. Normanno, N. *et al.* Epidermal growth factor receptor (EGFR) signaling in cancer. *Gene*
62 **366**, 2–16 (2006).
- 63 4. Tang, X. *et al.* Epidermal growth factor receptor abnormalities in the pathogenesis and
64 progression of lung adenocarcinomas. *Cancer Prev. Res. Phila. Pa* **1**, 192–200 (2008).
- 65 5. Brand, T. M., Iida, M., Li, C. & Wheeler, D. L. The nuclear epidermal growth factor receptor
66 signaling network and its role in cancer. *Discov. Med.* **12**, 419–432 (2011).
- 67 6. Ghassemi, S. *et al.* Cells test substrate rigidity by local contractions on submicrometer
68 pillars. *Proc Natl Acad Sci U A* **109**, 5328–33 (2012).
- 69 7. Wolfenson, H. *et al.* Tropomyosin controls sarcomere-like contractions for rigidity sensing
70 and suppressing growth on soft matrices. *Nat Cell Biol* **18**, 33–42 (2016).
- 71 8. Kim, J.-H. & Asthagiri, A. R. Matrix stiffening sensitizes epithelial cells to EGF and enables
72 the loss of contact inhibition of proliferation. *J Cell Sci* **124**, 1280–1287 (2011).
- 73 9. Wang, Y. *et al.* Pseudopodium-enriched atypical kinase 1 regulates the cytoskeleton and
74 cancer progression [corrected]. *Proc Natl Acad Sci U A* **107**, 10920–5 (2010).
- 75 10. Xu, K.-P., Yin, J. & Yu, F.-S. X. SRC-family tyrosine kinases in wound- and ligand-induced
76 epidermal growth factor receptor activation in human corneal epithelial cells. *Invest.*
77 *Ophthalmol. Vis. Sci.* **47**, 2832–2839 (2006).
- 78 11. Iskratsch, T. *et al.* FHOD1 Is Needed for Directed Forces and Adhesion Maturation during
79 Cell Spreading and Migration. *Dev Cell* **27**, 545–59 (2013).

Supplementary Figure 1




81

82 **Supplementary Figure 1** CUs detection method and definition of active area. **a**, actual CUs
83 detected in the active area by the automated program. Shown is a frame from a time-lapse movie
84 of a cell spreading on FN-coated 17.2 kPa pillars. Arrows represent pillar movement: red,
85 detected CUs; yellow, non-CUs. Green circles marked correctly identified CU; red circle marked
86 incorrectly detected CU. Success rate= $97.47 \pm 0.75\%$. Cell edge marked in blue. **b**, cell edge
87 marked in orange and blue correspond to time 120 min and 130 min respectively. Active area is
88 defined as the area where the cell edge moves outwards. **c**, number of CUs per second of the cell
89 in **b** monitored from 2h to 3h. The left and the right plots show the number of CUs in the active
90 and static area, respectively.

91

Supplementary Figure 2



92


93

94 **Supplementary Figure 2** Active area and pEGFR distribution disrupted by EGFR inhibitor and
 95 whole cell area on FN coated flat PDMS substrates. **a**, active area was measured in intervals of
 96 10 minutes. Cells with and without EGFR inhibitor treatment in medium lacking serum were
 97 monitored on rigid (top panel) and soft (bottom panel) pillar substrates for over 7 hours. **b**,
 98 phosphorylated EGFR lost co-localization with paxillin with EGFR inhibitor (gefitinib, 10 nM)
 99 treatment on rigid pillar substrate. **c**, Whole cell area of WT MEFs when spread on FN coated
 100 soft and stiff flat PDMS substrate with or without EGFR inhibitor. Error bars show standard error
 101 of the mean.


Supplementary Figure 3

a


Cos-7 + EGFP-myosin IIA




b



c




d



103 **Supplementary Figure 3** Confirmation of EGFR and HER2 involvement in Cos-7 and WT
 104 MEFs using small molecule inhibitors and inactive HER2 point mutant. **a**, Cos-7 cells expressing
 105 myosin IIA were spread on rigid pillars with or without EGFR and/or HER2 inhibitor or PP2.
 106 Further, Cos-7 cells were transfected with HER2 mutant (Y877F) in combination with the
 107 mentioned inhibitors. The arrows in the inset show pillar displacements. **b**, Whole cell area and
 108 contractile unit count for the first hour of spreading. **c**, WT MEFs and cells with knock-down of
 109 EGFR stained for total EGFR. Average total intensity is also shown to signify the extent of
 110 knock-down. 22 cells were analyzed for each case. **d**, Whole cell area of EGFR knock-down
 111 cells as a function of time. 18 cells were analyzed from 3 independent experiments. Error bars
 112 show standard error of the mean.

113

Supplementary Figure 4





114

115

116 **Supplementary Figure 4** Quantification of pEGFR distribution at cells edges. **a**, Average
 117 Intensity of pEGFR was calculated in Area 1 and Area 2 as shown. Area 1 is defined as a band
 118 across the cell edge with a width of ~4-5 μm . Intensity ratio is calculated by dividing the
 119 mentioned average from Area 1 by that of Area 2. This calculated Intensity ratio is a measure of
 120 the peripheral localization of pEGFR. In the following plots intensity ratio is plotted for the
 121 mentioned cells on stiff and soft substrates. **b**, WT cells stained for pEGFR Y1173. **c**, WT cells
 122 stained for pEGFR Y1068. **d**, WT cells stained for pEGFR Y845. **e**, SYF cells stained for
 123 pEGFR Y1068. **f**, SYF stably expressing YES stained for pEGFR Y1068. **g**, WT cells stimulated
 124 with EGF and then stained for pEGFR Y1068.

Supplementary Figure 5




125

126

127 **Supplementary Figure 5** Establishing the connection between SFKs and EGFR in cell
 128 spreading and adhesions. **a**, Active area of WT MEFs on stiff and soft pillars, with or without
 129 PP2. **b**, SYF cells and respective knock ins stained for Paxillin and pEGFR after 30 min of
 130 spreading on glass. **c**, Pearson correlation coefficient between paxillin and pEGFR in peripheral
 131 zone of cells as defined by Area 1 in Supplementary Figure 4a. $n > 10$. 3 independent experiments.
 132 Error bars represent standard error of the mean.

Supplementary Figure 6



133

134 **Supplementary Figure 6** EGF stimulation of cell edge and CU activity. **a**, Kymograph of cell
 135 edge after EGF addition at $t=0$ minutes. **b**, Plot of fraction of contractile unit force in total force
 136 exerted by the active area of a cell upon EGF addition. **c**, Active area of the cell with or without
 137 EGFR inhibitor when stimulated by EGF. **d**, Staining for paxillin and phosphorylated EGFR on
 138 rigid and soft substrates before (0 min) and after (8 min) addition of EGF. Scale bar is 10 μm .
 139 Error bars show standard error of the mean.